American Journal of Pediatrics

| Peer-Reviewed |

Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia

Received: 18 April 2020    Accepted: 6 May 2020    Published: 15 May 2020
Views:       Downloads:

Share This Article

Abstract

In recent years, an increase in dysmenorrhea among adolescents has been observed worldwide. Oral contraceptives are used in gynaecological practice to correct this condition. However, the prescription of drugs belonging to this group often misses the risk of developing vascular complications, such as cerebral venous thrombosis and cerebral venous infarction. Due to the growing percentage of patients with congenital genetic mutations, it is relevant and reasonable to consider the risk factors and clinical signs of venous infarction in adolescents. First, it is necessary to exclude congenital thrombophilia, factor V Leiden and prothrombin G20210A gene mutations, and deficiency of proteins C, S and antithrombin. Of particular notice are the young patients and adolescents with complaints of a first-time, intense, poorly treatable headache (or headache in anamnesis), changes in the eye fundus (edematous, hyperemic optic disks; dilated, plethoric veins in the fundus of the eye). In such cases, a thorough medical history is extremely important, including, in particular, detection of an infectious process, traumatic brain injury, venous thrombosis of any localization; the use of drugs (especially hormonal ones) that can provoke the development of a hypercoagulable state; and investigation of the family history. These measures will help to prevent development of a cerebral venous circulation disorder (venous infarction).

DOI 10.11648/j.ajp.20200603.15
Published in American Journal of Pediatrics (Volume 6, Issue 3, September 2020)
Page(s) 199-206
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Venous Infarction, Thrombophilia, Oral Contraceptives

References
[1] Uvarova EV. Pathology of the reproductive system in childhood and adolescence. Gynecology. National leadership. A brief edition. Eds. Savelyeva GM, Sukhikh GT, Manukhina IB. M.: GEOTAR-Media. 2013; 186-193. (In Russ.).
[2] Bernardine H Stegeman, Marcos de Bastos, Frits R Rosendaal, A van Hylckama Vlieg, Frans M Helmerhorst, Theo Stijnen, Olaf M Dekkers. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5298 (Published 12 September 2013). Cite this as: BMJ 2013; 347: f5298.
[3] Saposnik G., Barinagarrementeria F., Brown R. D., Bushnell C. D., Cucchiara B., Cushman M., deVeber G., Ferro J. M., Tsai F. Y; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011; 42: 1158-1192. doi: 10.1161/STR.0b013e31820a8364.
[4] Makarova T. A., Sotnikov A. Levin O. S. Venous thrombosis of the transverse sinus with hemorrhagic infarction and pure alexia is presented J. Nevrol. 2013; №4: 23: 29-33. (In Russ.)].
[5] Amoozegar F., Ronksley P. E., Sauve R., Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front. Neurol. 2015 Feb 2; 6: 7. (epub ahead of print). doi: 10.3389/fneur. 2015.00007.
[6] Fedin A., Ermoshkina N., Putilina, M., Vasilyev, Yu., Kozlov, M., Sidelnikova L., Snigireva T. Peculiarities of clinics and diagnosis of cerebral venous thrombosis // Clinical physiology of blood circulation, 2014: No. 1: 32-43. (In Russ.).
[7] Heit John A. Thrombophilia: Clinical and Laboratory Assessment and Management. / John A. Heit // Consultative Hemostasis and Thrombosis: Third Edition. Elsevier Inc. - 2013. - p. 205-239.
[8] Garcia-Horton A, Kovacs MJ, Abdulrehman J, Taylor JE, Sharma S, Lazo-Langner A. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res. 2017 Jan; 149: 76-80. doi: 10.1016/j.thromres.2016.11.023. Epub 2016 Dec 1.
[9] Dag Z. O. I., Işik Y. I., Simsek Y. I., Tulmac O. B. I., Demiray D. I. HELLP Syndrome and Cerebral Venous Sinus Thrombosis Associated with Factor V Leiden Mutation during Pregnancy//Case Rep Obstet Gynecol. 2014; 2014: 582-589. doi: 10.1155/2014/582890.
[10] Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015 Jan; 58 (1): 1-10. doi: 10.1016/j.ejmg.2014.10.004. Epub. 2014 Nov 4.
[11] Kang S, Zhao X, Liu L, Wu W, Zhang D. Association of the C677T polymorphism in the MTHFR gene with hemorrhagic stroke: a meta-analysis Genet Test Mol Biomarkers. 2013 May; 17 (5): 412-7. doi: 10.1089/gtmb.2012.0295. Epub 2013 Feb 21.
[12] Sodavarapu S., Ali SW., Goyal M. Cerebral Venous Sinus Thrombosis with Bilateral Abducens Palsy in a Patient with Heterozygous Prothrombin G20210A Mutation. Cureus. 2019 Nov 11; 11 (11): e6124. doi: 10.7759/cureus.6124.
[13] Putilina M. V. Endothelium as a target of new therapeutic strategies in vascular diseases of the brain. Journal of neurology and psychiatry. S. S. Korsakova, 2017; 117 (10): 122-130. (In Russ).
[14] Madison JA1, 2, 3, Duarte-García A4, 5, 3, Zuo Y1, Knight JS1. Treatment of thrombotic antiphospholipid syndrome in adults and children. Curr Opin Rheumatol. 2020 Mar 13. doi: 10.1097/BOR.0000000000000702. [Epub ahead of print].
[15] Chaturvedi S., McCrae K. R. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017 Nov; 31 (6): 406-417. doi: 10.1016/j.blre.2017.07.006. Epub 2017 Jul 30.
[16] Semenov S. E., Moldavskaia I. V., Yurkevich E. A., Shatokhina M. G., Semenov A. S. Diagnosis of venous ischemic stroke. Part I (Clinical polymorphism). A review article. Complex Issues of Cardiovascular Diseases. 2019; 8 (2): 125-134. DOI: 10.17802/2306-1278-2019-8-2-125-134.
[17] Ramsey R. R., Ryan J. L, Hershey A. D, Powers S. W, Aylward B. S, Hommel K. A. Treatment adherence in patients with headache: a systematic review. Headache. 2014 May; 54 (5): 795-816. doi: 10.1111/head.12353. Epub 2014 Apr 17.
[18] Ryskeldiyev N. A., Zhumadildina A. Zh., Teltayev D. K., Olenbai G. I., Mustafin Kh. A. Dural plasty in the posterior cranial fossa. Neyrokhirurgiya i nevrologiya Kazakhstana 2013; 4 (33): 18-22.
[19] Auezova R. Zh., Moldabekov A. Ye., Tleubergenov M. A., A. K., Doskaliyev A. Zh. Brain Venous infraction after convexital meningioma excision J. Neurosurgery and neurology of Kazakhstan 2014 №1 (34): 20-24.
[20] Mashin V. V., Belova L. A., Moiseev M. YU., Proshin A. N. A comparative clinical and neuroimaging study of venous and arterial strokes. Annals of Clinical and Experimental Neurology. 2015; 4: 24-31. (In Russian).
[21] Crous-Bou M., Harrington L. B., Kabrhel Ch. Environmental and genetic risk factors associated with venous thromboembolism Semin Thromb Hemost. 2016 Nov; 42 (8): 808–820. Published online 2016 Oct 20. doi: 10.1055/s-0036-1592333.
[22] Tasdemir S, Erdem HB, Sahin I, Ozel L, Ozdemir G, Eroz R, Tatar A. Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g. 20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI- 1, β-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes. Neuromolecular Med. 2016 Jun; 18 (2): 170-6. doi: 10.1007/s12017-016-8386-x. Epub 2016 Mar 7.
[23] Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies D. Erkan and S. S. Pierangeli, DOI 10.1007/978-1-4614-3194-7_17, Springer Science+Business Media New York 2012.
[24] Prevention of VTE in Nonorthopedic Surgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141 (2) (Suppl): e227S–e277S.
[25] VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141 (2 Suppl): e691S-736S.
Cite This Article
  • APA Style

    Putilina Marina, Teplova Nataliya, Dvornikov Anton. (2020). Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia. American Journal of Pediatrics, 6(3), 199-206. https://doi.org/10.11648/j.ajp.20200603.15

    Copy | Download

    ACS Style

    Putilina Marina; Teplova Nataliya; Dvornikov Anton. Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia. Am. J. Pediatr. 2020, 6(3), 199-206. doi: 10.11648/j.ajp.20200603.15

    Copy | Download

    AMA Style

    Putilina Marina, Teplova Nataliya, Dvornikov Anton. Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia. Am J Pediatr. 2020;6(3):199-206. doi: 10.11648/j.ajp.20200603.15

    Copy | Download

  • @article{10.11648/j.ajp.20200603.15,
      author = {Putilina Marina and Teplova Nataliya and Dvornikov Anton},
      title = {Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia},
      journal = {American Journal of Pediatrics},
      volume = {6},
      number = {3},
      pages = {199-206},
      doi = {10.11648/j.ajp.20200603.15},
      url = {https://doi.org/10.11648/j.ajp.20200603.15},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20200603.15},
      abstract = {In recent years, an increase in dysmenorrhea among adolescents has been observed worldwide. Oral contraceptives are used in gynaecological practice to correct this condition. However, the prescription of drugs belonging to this group often misses the risk of developing vascular complications, such as cerebral venous thrombosis and cerebral venous infarction. Due to the growing percentage of patients with congenital genetic mutations, it is relevant and reasonable to consider the risk factors and clinical signs of venous infarction in adolescents. First, it is necessary to exclude congenital thrombophilia, factor V Leiden and prothrombin G20210A gene mutations, and deficiency of proteins C, S and antithrombin. Of particular notice are the young patients and adolescents with complaints of a first-time, intense, poorly treatable headache (or headache in anamnesis), changes in the eye fundus (edematous, hyperemic optic disks; dilated, plethoric veins in the fundus of the eye). In such cases, a thorough medical history is extremely important, including, in particular, detection of an infectious process, traumatic brain injury, venous thrombosis of any localization; the use of drugs (especially hormonal ones) that can provoke the development of a hypercoagulable state; and investigation of the family history. These measures will help to prevent development of a cerebral venous circulation disorder (venous infarction).},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Venous Cerebral Infarction Caused by Intake of Hormonal Contraceptives in Adolescents with Congenital Thrombophilia
    AU  - Putilina Marina
    AU  - Teplova Nataliya
    AU  - Dvornikov Anton
    Y1  - 2020/05/15
    PY  - 2020
    N1  - https://doi.org/10.11648/j.ajp.20200603.15
    DO  - 10.11648/j.ajp.20200603.15
    T2  - American Journal of Pediatrics
    JF  - American Journal of Pediatrics
    JO  - American Journal of Pediatrics
    SP  - 199
    EP  - 206
    PB  - Science Publishing Group
    SN  - 2472-0909
    UR  - https://doi.org/10.11648/j.ajp.20200603.15
    AB  - In recent years, an increase in dysmenorrhea among adolescents has been observed worldwide. Oral contraceptives are used in gynaecological practice to correct this condition. However, the prescription of drugs belonging to this group often misses the risk of developing vascular complications, such as cerebral venous thrombosis and cerebral venous infarction. Due to the growing percentage of patients with congenital genetic mutations, it is relevant and reasonable to consider the risk factors and clinical signs of venous infarction in adolescents. First, it is necessary to exclude congenital thrombophilia, factor V Leiden and prothrombin G20210A gene mutations, and deficiency of proteins C, S and antithrombin. Of particular notice are the young patients and adolescents with complaints of a first-time, intense, poorly treatable headache (or headache in anamnesis), changes in the eye fundus (edematous, hyperemic optic disks; dilated, plethoric veins in the fundus of the eye). In such cases, a thorough medical history is extremely important, including, in particular, detection of an infectious process, traumatic brain injury, venous thrombosis of any localization; the use of drugs (especially hormonal ones) that can provoke the development of a hypercoagulable state; and investigation of the family history. These measures will help to prevent development of a cerebral venous circulation disorder (venous infarction).
    VL  - 6
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation

  • Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation

  • Department of Dermatology and Venereology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation

  • Sections